European guidelines for quality assurance in cervical cancer screening. Second edition-summary document

Annals of Oncology

Volumn 21, Issue 3, 2010, Pages 448-458

  Arbyn, M ^a   Anttila, A ^b   Jordan, J ^c   Ronco, G ^d   Schenck, U ^e   Segnan, N ^d   Wiener, H ^f   Herbert, A ^g   von Karsa, L ^h  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b FINNISH CANCER REGISTRY   (Finland)

^c BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^d Reference Centre for Cancer Epidemiology and Prevention   (Italy)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^h INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Europe; Guidelines; Quality assurance; Screening

Indexed keywords

CANCER VACCINE; WART VIRUS VACCINE;

CANCER PREVENTION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; EUROPE; FALSE NEGATIVE RESULT; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HEALTH PRACTITIONER; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; MEDICAL SOCIETY; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS;

EID: 77949583147     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp471     Document Type: Review

References (31)

1. Arbyn M, Raifu AO, Autier P, Ferlay J. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007; 18: 1708-1715.
2. Arbyn M, Autier P, Ferlay J. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Ann Oncol 2007; 18: 1423-1425.
3. Miller AB. Cervical Cancer Screening Programmes: Managerial Guidelines. Geneva, Switzerland: World Health Organisation 1992.
4. International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention. Vol. 10: Cervix Cancer Screening. Lyon, France: IARC Press 2005.
5. Coleman D, Day N, Douglas G et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Europe against cancer programme. Eur J Cancer 1993; 29A (Suppl 4): S1-S38.
6. European Commission. In Arbyn M, Anttila A, Jordan J et al. (eds), European Guidelines for Quality Assurance in Cervical Cancer Screening, 2nd edition. Luxembourg: Office for Official Publications of the European Communities 2008. 1-291.
7. von Karsa L, Anttila A, Ronco G et al. Cancer Screening in the European Union. Report on the Implementation of the Council Recommendation on Cancer Screening. First Report. City of Luxembourg, Grand Duchy of Luxembourg: Services of the European Commission 2008.
8. European Commission. Report from the Commission to the Council, the European Parliament, the European Economic and Social Committee and the Committee of the Regions. Implementation of the Council Recommendation of 2 December 2003 on Cancer Screening (2003/878/EC). Brussels, Belgium: Commission of the European Communities 2008; 22.12.2008. COM 2008; 882 final.
9. Cogliano V, Baan R, Straif K et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6: 204.
10. Muñoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
11. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 2007; 38: 189-197.
12. Council of the European Union. Council Recommendation of 2 December 2003 on Cancer Screening (2003/878/EC). Off J Eur Union 2003; 878: 34-38.
13. Advisory Committee on Cancer Prevention. Recommendations on cancer screening in the European Union. Eur J Cancer 2000; 36: 1473-1478.
14. WHO. Comprehensive Cervical Cancer Control: A Guide to Essential Practice. Geneva, Switzerland: WHO 2006.
15. Boyle P, Autier P, Bartelink H et al. European Code Against Cancer and scientific justification: third version (2003). Ann Oncol 2003; 14: 973-1005.
16. Giordano L, Webster P, Anthony C et al. Improving the quality of communication in organised cervical cancer screening programmes. Patient Educ Couns 2008; 72: 130-136.
17. Ronco G, Cuzick J, Pierotti P et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ 2007; 335: 28.
18. Arbyn M, Herbert A, Schenck U et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007; 18: 133-139.
19. Wiener HG, Klinkhamer P, Schenck U et al. European guidelines for quality assurance in cervical cancer screening: recommendations for cytology laboratories. Cytopathology 2007; 18: 67-78.
20. Herbert A, Bergeron C, Wiener H et al. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology. Cytopathology 2007; 18: 213-219.
21. Jordan J, Arbyn M, Martin-Hirsch P et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology 2008; 19: 342-354.
22. Arbyn M, Buntinx F, Van Ranst M et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J. Natl Cancer Inst 2004; 96: 280-293.
23. Jordan J, Martin-Hirsch P, Arbyn M et al. European guidelines for clinical management of abnormal cervical cytology, part 2. Cytopathology 2009; 20: 5-16.
24. WHO. Cancer Control: Knowledge into Action. WHO Guide for Effective Programmes. Planning. Geneva, Switzerland: WHO 2006.
25. European Parliament. European Parliament resolution of 10 April on combating cancer in the enlarged European Union 2008; Report No.: P6_TA- PROV(2008)0121, Brussels, Belgium.
26. Council of the European Union. Council conclusions on reducing the burden of cancer. In 2876th Employment, Social Policy, Health and Consumer Affairs Council meeting. Luxembourg, 10 June 2008. Brussels, Belgium: Press Office of the Council of the European Union 2008.
27. Arbyn M, Dillner J. Appendix 2: HPV vaccination. In Arbyn M, Anttila A, Ronco G et al. (eds), European Guidelines for Quality Assurance in Cervical Cancer Screening, 2nd edition. City of Luxembourg, Grand Duchy of Luxembourg: Office for Official Publications of the European Communities 2009; 267-282.
28. Muñoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-285.
29. Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621-632.
30. Ronco G, von Karsa L, Anttila A. Key performance indicators. In Arbyn M, Anttila A, Jordan J et al. (eds), European Guidelines for Quality Assurance in Cervical Cancer Screening, 2nd edition. City of Luxembourg, Grand Duchy of Luxembourg: Office for Official Publications of the European Communities 2008; 231-242.
31. Anttila A, Ronco G, Lynge E et al. Epidemiological guidelines for quality assurance in cervical cancer screening. In Arbyn M, Anttila A, Jordan J et al. (eds), European Guidelines for Quality Assurance in Cervical Cancer Screening, 2nd edition. City of Luxembourg, Grand Duchy of Luxembourg: Office for Official Publications of the European Communities 2008; 11-68.